Hartaj Singh
Stock Analyst at Oppenheimer
(1.45)
# 3,286
Out of 4,843 analysts
101
Total ratings
38.61%
Success rate
-11.23%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $184 → $123 | $37.60 | +227.13% | 10 | May 7, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $490.28 | +83.57% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $110.08 | +13.55% | 15 | Apr 25, 2025 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $4.76 | +488.24% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $318.85 | +88.18% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $442.05 | +22.16% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $26.56 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.46 | +584.93% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.44 | +4,066.67% | 5 | May 30, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.77 | +408.47% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.00 | +1,900.00% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $7.59 | +190.05% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.71 | +37,911.70% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $18.22 | +64.70% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $184 → $123
Current: $37.60
Upside: +227.13%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $490.28
Upside: +83.57%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $110.08
Upside: +13.55%
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $4.76
Upside: +488.24%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $318.85
Upside: +88.18%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $442.05
Upside: +22.16%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $26.56
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.46
Upside: +584.93%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.44
Upside: +4,066.67%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.77
Upside: +408.47%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.00
Upside: +1,900.00%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $7.59
Upside: +190.05%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.71
Upside: +37,911.70%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $18.22
Upside: +64.70%